NAD+ (nicotinamide adenine dinucleotide) — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 6 sources[1,2,3,4,5,6].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin… | Cell Metabolism | 2015 |
| 2 | First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics | British Journal of Pharmacology | 2014 |
| 3 | General Chapter ⟨85⟩ Bacterial Endotoxins Test | United States Pharmacopeia — National Formulary (USP–NF) | 2024 |
| 4 | General Chapter ⟨71⟩ Sterility Tests | United States Pharmacopeia — National Formulary (USP–NF) | 2024 |
| 5 | ICH Q1A(R2) Stability Testing of New Drug Substances and Products | ICH Harmonised Tripartite Guideline | 2003 |
| 6 | Related impurities in peptide medicines | Journal of Pharmaceutical and Biomedical Analysis | 2014 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 0 | — |
| Evidence syntheses | 0 | none |
| Comment periods | 1 | Draft monograph: NAD+ (nicotinamide adenine dinucleotide) |
| Indication assessments | 4 | Ageing · Alcohol use disorder · Cognition · Mitochondrial disease |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009 · PMID 25738459
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology 2014;171(8):2029–2050. doi:10.1111/bph.12461 · PMID 24117165
- United States Pharmacopeial Convention. General Chapter ⟨85⟩ Bacterial Endotoxins Test. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- United States Pharmacopeial Convention. General Chapter ⟨71⟩ Sterility Tests. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q1A(R2) Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline 2003;Step 4 version. identifier not held by the Institute
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.